Concord Biotech Limited IPO: Issue Price, Listing Gain and Share Price Now
Concord Biotech Limited listed on 18-Aug-2023 at ₹941.85 against an issue price of ₹741 , a listing gain of +27.11%. It last traded at ₹1,576. This page is the record of that issue and what has happened to it since — reported figures only.
Concord Biotech Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹741 |
| Listing price (listing-day close) | ₹941.85 |
| Listing gain | +27.11% |
| Price now | ₹1,576 |
| Change from issue price | +112.69% |
| Change from listing-day close | +67.33% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Concord Biotech Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹741 |
| Issue size | ₹1,550.52 Cr |
| Offer for sale | ₹1,550.52 Cr |
| Issue opened | 04-Aug-2023 |
| Issue closed | 08-Aug-2023 |
| Listed on | 18-Aug-2023 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Kotak Mahindra Capital (left lead) |
How the Concord Biotech Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 67.67x |
| NII | 16.99x |
| Retail | 3.78x |
| Total | 24.87x |
Concord Biotech Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹16,520 Cr |
| Trailing P/E | 59.50x |
| Return on capital employed | 17.1% |
| Return on equity | 12.5% |
| 52-week high | ₹1,802 |
| 52-week low | ₹987 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Concord Biotech Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.